Additional file 9 of Large-scale copy number alterations are enriched for synthetic viability in BRCA1/BRCA2 tumors

Additional file 9: Table S8. Frequency of heterozygous and homozygous loss for clonogenic assay-validated genes in ER+ breast cancer and ovarian cancer that is HRD vs. HR proficient.

补充文件9：表S8。在雌激素受体阳性（ER+, Estrogen Receptor-positive）乳腺癌，以及同源重组缺陷（HRD, Homologous Recombination Deficiency）与同源重组功能完整（HR proficient）的卵巢癌中，经集落形成实验（clonogenic assay）验证的基因的杂合性缺失与纯合性缺失发生频率。